GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion
GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments. Efimosfermin, targeting steatotic liver disease and MASH, is expected to launch in 2029, with (...)
Site référencé: The Economic Times
The Economic Times
Sebi easing norms for foreign investors buying only government bonds
13/05/2025
L&T back on investor radar amid strong order book, hopes of margin improvement
13/05/2025
Expect a big move in metals ; stick to quality largecaps : Gautam Shah
13/05/2025
Virtual Galaxy Infotech IPO booked 23 times on Day 3 ; GMP indicates 53% listing premium
13/05/2025
Foreign investors continue to show confidence in India despite global uncertainty : Pratik Gupta
13/05/2025
Kotak Equities reshuffles model portfolio ; adds IndiGo, Pidilite ; reduces Dabur. Here’s what changed
13/05/2025
